Burning lung spots plus systemic therapy for liver cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether burning away a few cancer spots in the lungs (called ablation) can help people with liver cancer who are already on a systemic treatment. If you have stable liver cancer and only a few lung spots that haven't grown, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that has spread to your lungs, but only a few spots (up to 5) and no bigger than 5 cm (about 2 inches).
- You have been on a first-line cancer treatment (like a pill or IV therapy) for at least 3 months, and the cancer in your liver is stable or shrinking.
- Your liver is working fairly well (Child-Pugh class A or B), and you are able to do most daily activities (ECOG score 0 or 1).
- You are between 18 and 75 years old, and your overall health is good enough that you are expected to live at least 3 more months.
- Your blood counts and kidney function meet certain minimum levels (like enough white blood cells and platelets).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted procedure (ablation) to burn away cancer spots, when combined with lenvatinib and an immunotherapy drug (PD-1 inhibitor), can help control liver cancer that has spread to a few places. It's for people whose liver tumors are already responding to treatment.
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
This trial tests a combination of a focused radiation beam (SBRT) plus a pill that helps stop tumor blood vessel growth (lenvatinib) and a procedure that blocks blood flow to the tumor (TACE) for people with advanced liver cancer that has not yet spread outside the liver. The goal is to see if this triple therapy can improve outcomes without prior treatment.
This trial tests a combination of radiation therapy, an immunotherapy drug called camrelizumab, and a targeted therapy pill called apatinib for people with advanced liver cancer that has spread to the main blood vessel of the liver. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
This trial tests a new combination treatment that uses heat (ablation) and other therapies to destroy liver tumors. It's for people who cannot have surgery or choose not to, and whose tumor is a specific size.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.